DBM 1152A
Alternative Names: DBM-1152A; JKN-2304Latest Information Update: 10 Mar 2026
At a glance
- Originator Joincare Pharmaceutical
- Class Antiasthmatics; Antibronchitics; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease
- Phase I Bronchiectasis
Most Recent Events
- 25 Sep 2025 Joincare Pharmaceutical completes a phase-IIa clinical trials in Chronic obstructive pulmonary disease (Treatment-experienced) in China (Inhalation) (NCT07450482)